代谢相关脂肪性肝病性别、区域与种族差异   樊亚菲 王倩 李小珍 徐盈 李佳 周西

摘要/Abstract

摘要： 代谢相关脂肪性肝病(MAFLD)已成为全球最常见的慢性肝病之一,且为我国第一大慢性肝病,但我们对MAFLD在性别和种族差异方面的流行病学特征的了解仍十分有限。本文旨在分析和讨论MAFLD在性别、地域和种族方面的最新研究进展,重点围绕疾病的发病率、危险因素及并发症等内容展开论述,以期更好地理解和管理这些差异,为MAFLD的预防和治疗提供新的视角。未来仍需开展大样本、多中心研究,深入探究性别和种族的潜在机制,并开发适用于不同人群的评估工具和防治策略,以实现MAFLD的精准健康管理。

关键词: 代谢性脂肪性肝病, 性别, 种族, 差异

樊亚菲, 王倩, 李小珍, 徐盈, 李佳, 周西. 代谢相关脂肪性肝病性别、区域与种族差异樊亚菲王倩李小珍徐盈李佳周西[J]. 肝脏, 2025, 30(8): 1156-1160.

/ 推荐

参考文献

[1] Rinella M E, Neuschwander-Tetri B A, Siddiqui M S, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.
[2] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5):418-434.
[3] Riazi K, Azhari H, Charette J H, et al. The prevalence and incidence of NAFLD worldwide:a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861.
[4] Lou T W, Yang R X, Fan J G. The global burden of fatty liver disease: the major impact of China[J]. Hepatobiliary Surg Nutr, 2024, 13(1): 119-123.
[5] Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)[J]. EndocrPract, 2022, 28(5): 528-562.
[6] Duell P B, Welty F K, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association[J]. Arterioscler Thromb Vasc Biol, 2022, 42(6): e168-e185.
[7] Sun D Q, Targher G, Byrne C D, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease[J]. Hepatobiliary Surg Nutr, 2023, 12(3): 386-403.
[8] Nan Y, An J, Bao J, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol, 2021, 75(2): 454-461.
[9] Eslam M, Sanyal A J, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.
[10] Eslam M, Newsome P N, Anstee Q M, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202- 209.
[11] Eslam M, Sarin S K, Wong V W, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919.
[12] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79(6): 1542-1556.
[13] Qiu J, Kuang M, He S, et al. Gender perspective on the association between liver enzyme markers and non-alcoholic fatty liver disease: insights from the general population[J].Front Endocrinol (Lausanne),2023 ,14:1302322.
[14] Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)[J]. EndocrPract, 2022, 28(5): 528-562.
[15] Eslam M, Newsome P N, Anstee Q M, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.
[16] Song S J, Lai J C, Wong G L, et al. Can we use old NAFLD data under the new MASLD definition?[J]. J Hepatol, 2024, 80(2): e54-e56.
[17] Khramtsova E A, Davis L K, Stranger B E, et al. The role of sex in the genomics of human complex traits[J] Nat Rev Genet,2019,20(3):173-190.
[18] Oliva M, Muñoz-Aguirre M, Kim-Hellmuth S, et al. The impact of sex on gene expression across human tissues[J]. Science,2020,11:369(6509):eaba3066.
[19] Lou T W, Yang R X, Fan J G. The global burden of fatty liver disease: the major impact of China[J]. Hepatobiliary Surg Nutr, 2024, 13(1): 119-123.
[20] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864.
[21] Anderson E L, Howe L D, Jones H E, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis[J]. PLoS One,2015,10(10):e0140908.
[22] Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77( 4): 1335-1347.
[23] Li J, Zou B, Yeo Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5): 389-398.
[24] Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis [J].Hepatol Int,2020,14(2): 259-269.
[25] Rich N E, Noureddin M, Kanwal F, et al. Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA[J]. Lancet Gastroenterol Hepatol,2021, 6(6): 422-424.
[26] Ni L, Yu D, Wu T, et al.Gender-specific association between non-alcoholic fatty liver disease and type 2 diabetes mellitus among a middle-aged and elderly Chinese population: an observational study[J]. Medicine (Baltimore), 2021,100(6):e24743.
[27] Hong X, Guo Z, Yu Q. Hepatic steatosis in women with polycystic ovary syndrome [J].BMC Endocr Disord,2023,23(1):207.
[28] Cherubini A, Della Torre S, Pelusi S, et al. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease[J]. Trends Mol Med,2024,30(12):1126-1136.
[29] Bozdag G, Mumusoglu S, Zengin D,et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis[J]. Hum Reprod,2016,31(12):2841-2855.
[30] Teede H J, Misso M L, Costello M F, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Fertil Steril,2018,110(3):364-379.
[31] Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps [J].Hepatology,2019 ,70(4):1457-1469.
[32] Adjei N K, Samkange-Zeeb F, Boakye D,et al. Ethnic differences in metabolic syndrome in high-income countries: a systematic review and meta-analysis[J]. Rev Endocr Metab Disord,2024,25(4):727-750.
[33] Suzuki A, Abdelmalek M F, Schwimmer J B, et al.Association between puberty and features of nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol,2012,10(7):786-794.
[34] Smith S M, Yearsley M M, Levin D,et al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis[J].Clin Gastroenterol Hepatol,2017,15(1):127-131.
[35] Mohanty S R, Troy T N, Huo D, et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease[J]. J Hepatol, 2009,50(4): 797-804.
[36] Szanto K B, Li J, Cordero P,et al. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease[J]. Diabetes Metab Syndr Obes,2019, 12: 357-367.
[37] Ascha M S, Hanouneh I A, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J]. Hepatology,2010,51(6):1972-1978.
[38] Yang D, Hanna D L, Usher J, et al.Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis[J].Cancer,2014,120(23):3707-3716.
[39] Yasui K, Hashimoto E, Komorizono Y, et al.Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma[J].Clin Gastroenterol Hepatol,2011,9(5):428-433.
[40] Bengtsson B, Stal P, Wahlin S,et al. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis[J].Liver Int,2019,39(6):1098-1108.
[41] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.
[42] Hatano Y, VanWagner L B, Carnethon M R, et al. Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study[J]. Diabetologia,2023,66(7): 1235-1246.